What about the pharmaceutical sector? Five factors will support the business climate

"Pharmaceutical network market analysis" with the pharmaceutical sector short-term adjustment gradually in place, the pharmaceutical sector market is still favored by investors.
long-term, pharmaceutical stocks should focus on long-term investment, five positive factors will support the business climate of the pharmaceutical sector.
Q2, Q3 most pharmaceutical companies are expected to perform relatively well.
of this year, with the normalization of domestic epidemic prevention and control, production gradually recovered, some areas of rigid demand ushered in the anti-ballistic. in the first half of
, the revenue of more than 10 billion yuan is Shanghai Pharmaceuticals, Kyushua Tong and other nearly 20 pharmaceutical companies;
also from the listed pharmaceutical companies have disclosed the third quarter of the report, most of the results are positive.
Such as Enhua Pharmaceuticals' net profit attributable to shareholders of listed companies in January-September 2020 is expected to be 573 million to 677 million, a year-on-year change of 10.00% to 30.00%; 3.5 billion to 161 million, up 160.00% to 210.00% YoY, and Weikang Pharmaceuticals expects net profit of about RMB85.1 million to RMB93.5 million in the first three quarters of 2020, up 1.87% to 11.92% YoY.
is the third batch of drug collection policy pressure risks within the expected, is not expected to have an impact on the pharmaceutical sector.
, many medical people say that with the normalization of the collection, there is now almost no panic, because a good way to solve these problems has been found.
from the current environment, pharmaceutical stocks are still attracting market attention.
the first half of this year, pharmaceutical stocks have risen more and more, most of the valuation of pharmaceutical stocks have reached an all-time high.
the vaccine plates, especially in the biological sector, almost all of them doubled.
under the background of the normalization of the epidemic, people's awareness of health care is constantly improving, and with the increasing level of consumption, the industry is generally optimistic about pharmaceutical stocks, in different areas of advantage to do layout.
fourth is that vaccine and medical device innovation is in the initial stage of development.
limited by the level of productivity development, China's medical device industry as a whole started late, but with the strengthening of the country's overall strength and the improvement of the industrial base, the medical device industry is still in a golden period of rapid development.
this year, domestic IVD enterprises began to return to the local market, all over the country has issued a message that under certain conditions, priority procurement of domestic IVD equipment.
domestic equipment has the advantages of cost-effective and rapid response.
At present, many provinces in China are actively promoting the share of domestic large-scale medical equipment in medical institutions, is expected to accelerate domestic replacement, promote domestic IVD product innovation, drive the rapid development of the market, the market size is expected to exceed 760 billion yuan in 2020.
with the support of national policies and technological development and industrial upgrading of the medical device industry, it is expected to continue to maintain a good trend of high-speed growth and realize the vision of importing substitution from the low-end market to the high-end market.
domestic vaccine industry started relatively late, December 1, 2019 the official implementation of the Vaccine Management Law, marking China's biological products, especially the vaccine industry will enter a new stage of development.
2020, a large population base and potential demand are expected to drive the vaccine industry as policy drives and investment increases.
is that the risk for the pharmaceutical sector is that the plate's comparative advantage disappears, not the immediate.
The industry believes that if the pharmaceutical sector adjusts in the future, the high probability is not that factors within the industry dominate (e.g. policy, growth), but the weakening of the industry's comparative advantage (e.g. epidemic inflection point, cycle/financial sector rise, end-of-year vaccine phase III data blind).